US20020150921A1
(en)
*
|
1996-02-09 |
2002-10-17 |
Francis Barany |
Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
|
CZ301750B6
(cs)
|
1999-12-24 |
2010-06-09 |
Aventis Pharma Limited |
Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení
|
YU54202A
(sh)
*
|
2000-01-18 |
2006-01-16 |
Agouron Pharmaceuticals Inc. |
Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
|
US6897231B2
(en)
*
|
2000-07-31 |
2005-05-24 |
Signal Pharmaceuticals, Inc. |
Indazole derivatives as JNK inhibitors and compositions and methods related thereto
|
US20050009876A1
(en)
*
|
2000-07-31 |
2005-01-13 |
Bhagwat Shripad S. |
Indazole compounds, compositions thereof and methods of treatment therewith
|
US7211594B2
(en)
|
2000-07-31 |
2007-05-01 |
Signal Pharmaceuticals, Llc |
Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
|
WO2002016348A1
(fr)
*
|
2000-08-09 |
2002-02-28 |
Astrazeneca Ab |
Derives bicycliques antiangiogeniques
|
ES2302106T3
(es)
|
2000-09-11 |
2008-07-01 |
Novartis Vaccines And Diagnostics, Inc. |
Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
|
DE10046029A1
(de)
|
2000-09-18 |
2002-03-28 |
Bayer Ag |
Indazole
|
US6982274B2
(en)
|
2001-04-16 |
2006-01-03 |
Eisai Co., Ltd. |
1H-indazole compound
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7642278B2
(en)
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
EP1401831A1
(fr)
|
2001-07-03 |
2004-03-31 |
Chiron Corporation |
Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase
|
FR2827861B1
(fr)
|
2001-07-27 |
2004-04-02 |
Aventis Pharma Sa |
Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
|
US20040077702A1
(en)
*
|
2001-09-14 |
2004-04-22 |
Wen-Mei Fu |
Treatment of nuerodegenerative diseases
|
EP1432416B1
(fr)
|
2001-09-26 |
2011-01-19 |
Pfizer Italia S.r.l. |
Derives d'aminoindazole agissant comme inhibiteurs de la kinase, procede de production et compositions pharmaceutiques les contenant
|
JP4637481B2
(ja)
|
2001-10-19 |
2011-02-23 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン
|
FR2831536A1
(fr)
*
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
FR2831537B1
(fr)
*
|
2001-10-26 |
2008-02-29 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
|
IL161576A0
(en)
*
|
2001-10-26 |
2004-09-27 |
Aventis Pharma Inc |
Benzimidazoles and analogues and their use as protein kinases inhibitors
|
US6897208B2
(en)
|
2001-10-26 |
2005-05-24 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles
|
US7074805B2
(en)
*
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US6867320B2
(en)
*
|
2002-02-21 |
2005-03-15 |
Asahi Kasei Pharma Corporation |
Substituted phenylalkanoic acid derivatives and use thereof
|
NZ535349A
(en)
*
|
2002-03-08 |
2007-01-26 |
Signal Pharm Inc |
JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
|
FR2836914B1
(fr)
|
2002-03-11 |
2008-03-14 |
Aventis Pharma Sa |
Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
US7166293B2
(en)
|
2002-03-29 |
2007-01-23 |
Carlsbad Technology, Inc. |
Angiogenesis inhibitors
|
US20050119278A1
(en)
*
|
2002-05-16 |
2005-06-02 |
Che-Ming Teng |
Anti-angiogenesis methods
|
MXPA04011851A
(es)
*
|
2002-05-30 |
2005-03-31 |
Celgene Corp |
Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos.
|
IL164209A0
(en)
*
|
2002-05-31 |
2005-12-18 |
Eisai Co Ltd |
Pyrazole derivatives and pharmaceutical compositions containing the same
|
JP2004075673A
(ja)
*
|
2002-06-19 |
2004-03-11 |
Mitsubishi Chemicals Corp |
化合物およびこれを用いた有機電界発光素子
|
GB0218625D0
(en)
*
|
2002-08-10 |
2002-09-18 |
Astex Technology Ltd |
Pharmaceutical compounds
|
EP1545515A1
(fr)
|
2002-08-12 |
2005-06-29 |
Sugen, Inc. |
3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
|
US20040087642A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
|
EP1582211A1
(fr)
*
|
2002-12-03 |
2005-10-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de jnk
|
EA008501B1
(ru)
|
2002-12-19 |
2007-06-29 |
Пфайзер Инк. |
2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
|
US20050019366A1
(en)
*
|
2002-12-31 |
2005-01-27 |
Zeldis Jerome B. |
Drug-coated stents and methods of use therefor
|
US6933311B2
(en)
*
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
BRPI0407618A
(pt)
*
|
2003-02-21 |
2006-02-21 |
Pfizer |
derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
|
DE602004029145D1
(de)
|
2003-02-27 |
2010-10-28 |
Palau Pharma Sa |
Pyrazolopyridin-derivate
|
ES2214150B1
(es)
*
|
2003-02-27 |
2005-12-01 |
J. URIACH & CIA S.A. |
"nuevos derivados de pirazolopiridinas".
|
DE602004006852D1
(de)
|
2003-04-17 |
2007-07-19 |
Janssen Pharmaceutica Nv |
2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
|
FR2854159B1
(fr)
*
|
2003-04-25 |
2008-01-11 |
Aventis Pharma Sa |
Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
|
US7015233B2
(en)
|
2003-06-12 |
2006-03-21 |
Abbott Laboratories |
Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
ITRM20030355A1
(it)
*
|
2003-07-18 |
2005-01-19 |
Sigma Tau Ind Farmaceuti |
Composti ad attivita' citotossica derivati della combretastatina.
|
KR101204247B1
(ko)
|
2003-07-22 |
2012-11-22 |
아스텍스 테라퓨틱스 리미티드 |
3,4-이치환된 1h-피라졸 화합물 및 그의 시클린 의존성키나제 (cdk) 및 글리코겐 합성효소 키나제-3(gsk-3) 조정제로서 용도
|
CA2518951A1
(fr)
*
|
2003-07-30 |
2005-02-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de la proteine kinase
|
EP1652842B1
(fr)
*
|
2003-07-30 |
2012-04-11 |
Kyowa Hakko Kirin Co., Ltd. |
Derivés d'Indazole
|
US7008953B2
(en)
*
|
2003-07-30 |
2006-03-07 |
Agouron Pharmaceuticals, Inc. |
3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
|
US20050090529A1
(en)
*
|
2003-07-31 |
2005-04-28 |
Pfizer Inc |
3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
|
US7511145B2
(en)
*
|
2003-08-01 |
2009-03-31 |
Genelabs Technologies, Inc. |
Bicyclic heteroaryl derivatives
|
US20050113576A1
(en)
*
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
WO2005014554A1
(fr)
*
|
2003-08-08 |
2005-02-17 |
Astex Therapeutics Limited |
Composes 1h-indazole-3-carboxamide utilises comme modulateurs de la mapkap kinase
|
EP1660427A4
(fr)
|
2003-08-14 |
2006-12-20 |
Asahi Kasei Pharma Corp |
Derive d'acide arylalcanoique substitue et son utilisation
|
JP2005089457A
(ja)
*
|
2003-09-03 |
2005-04-07 |
Yung Shin Pharmaceutical Industry Co Ltd |
骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
|
US6984652B2
(en)
*
|
2003-09-05 |
2006-01-10 |
Warner-Lambert Company Llc |
Gyrase inhibitors
|
MY144339A
(en)
*
|
2003-09-08 |
2011-08-29 |
Aventis Pharma Inc |
Thienopyrazoles
|
TWI344961B
(en)
*
|
2003-10-15 |
2011-07-11 |
Ube Industries |
Novel indazole derivative
|
BRPI0416266A
(pt)
*
|
2003-11-06 |
2007-01-09 |
Celgene Corp |
método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
|
EP2762475A1
(fr)
|
2003-11-07 |
2014-08-06 |
Novartis Vaccines and Diagnostics, Inc. |
Sels pharmaceutiquement acceptables de composés de quinoline et leur utilisation médicale
|
US20060179711A1
(en)
*
|
2003-11-17 |
2006-08-17 |
Aerogrow International, Inc. |
Devices and methods for growing plants
|
EP2065383A1
(fr)
|
2003-11-19 |
2009-06-03 |
Signal Pharmaceuticals, Inc. |
Composés d'indazoles et procédés d'utilisation associés en tant qu'inhibiteurs de kinase de protéine
|
US7488817B2
(en)
*
|
2004-02-02 |
2009-02-10 |
The Trustees Of The University Of Pennsylvania |
Metal complex protein kinase inhibitors
|
WO2005094823A1
(fr)
*
|
2004-03-30 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
INHIBITEUR DE Flt-3
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
GB0409080D0
(en)
*
|
2004-04-23 |
2004-05-26 |
Biofocus Discovery Ltd |
Compounds which interact with protein kinases
|
AU2005266494B2
(en)
*
|
2004-07-27 |
2009-09-10 |
Novartis Ag |
Inhibitors of Hsp90
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
FR2876584B1
(fr)
*
|
2004-10-15 |
2007-04-13 |
Centre Nat Rech Scient Cnrse |
Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
|
US20060116519A1
(en)
*
|
2004-11-17 |
2006-06-01 |
Agouron Pharmaceuticals, Inc. |
Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
|
WO2006054143A1
(fr)
*
|
2004-11-17 |
2006-05-26 |
Pfizer Inc. |
Formes polymorphes de {5-[3-(4,6-difluoro-1h-benzimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
|
CA2588558A1
(fr)
*
|
2004-11-23 |
2006-06-01 |
Celgene Corporation |
Procedes et compositions permettant d'utiliser des inhibiteurs jnk pour traiter et gerer une blessure du systeme nerveux central
|
AU2005321091B2
(en)
|
2004-12-30 |
2012-04-12 |
Astex Therapeutics Limited |
Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases
|
US20080161251A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
JP5475235B2
(ja)
|
2005-01-21 |
2014-04-16 |
アステックス・セラピューティクス・リミテッド |
医薬化合物
|
CA2596527C
(fr)
|
2005-01-27 |
2013-02-12 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur d'igf-1r
|
GT200600042A
(es)
|
2005-02-10 |
2006-09-27 |
Aventis Pharma Inc |
Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
|
US20070004777A1
(en)
*
|
2005-03-23 |
2007-01-04 |
Bhagwat Shripad S |
Methods for treating or preventing acute myelogenous leukemia
|
PT1869020E
(pt)
|
2005-03-29 |
2010-12-23 |
Icos Corp |
Derivados de heteroaril-ureia úteis para a inibição de chk1
|
JP2008540345A
(ja)
*
|
2005-04-29 |
2008-11-20 |
セルジーン・コーポレーション |
1−(5−(1h−1,2,4−トリアゾール−5−イル)(1h−インダゾール−3−イル))−3−(2−ピペリジルエトキシ)ベンゼンの固体形態
|
ATE530533T1
(de)
|
2005-05-17 |
2011-11-15 |
Novartis Ag |
Verfahren zur synthese heterocyclischer verbindungen
|
WO2006130673A1
(fr)
|
2005-05-31 |
2006-12-07 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines utilisees pour traiter des troubles dont la mediation est assuree par des kinases
|
US7470787B2
(en)
|
2005-07-11 |
2008-12-30 |
Aerie Pharmaceuticals, Inc. |
Isoquinoline compounds
|
WO2007058626A1
(fr)
*
|
2005-11-16 |
2007-05-24 |
S*Bio Pte Ltd |
Composes d'indazole
|
PT1957074E
(pt)
|
2005-11-29 |
2014-06-25 |
Novartis Ag |
Formulações de quinolinonas
|
KR20070077468A
(ko)
*
|
2006-01-23 |
2007-07-26 |
크리스탈지노믹스(주) |
단백질 키나아제 활성을 저해하는 이미다조피리딘 유도체,이의 제조방법 및 이를 함유하는 약학 조성물
|
AU2007213452A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Biomarin Iga Limited |
Treatment of Duchenne muscular dystrophy
|
JP2009530337A
(ja)
*
|
2006-03-23 |
2009-08-27 |
エフ.ホフマン−ラ ロシュ アーゲー |
置換インダゾール誘導体、その製造方法、及びその薬剤としての利用法
|
CN101484427A
(zh)
|
2006-06-30 |
2009-07-15 |
协和发酵麒麟株式会社 |
Abl激酶抑制剂
|
US20090209537A1
(en)
*
|
2006-06-30 |
2009-08-20 |
Kyowa Hakko Kirin Co., Ltd. |
Aurora inhibitors
|
JPWO2008020606A1
(ja)
*
|
2006-08-16 |
2010-01-07 |
協和発酵キリン株式会社 |
血管新生阻害剤
|
CA2661898A1
(fr)
*
|
2006-08-25 |
2008-02-28 |
Abbott Laboratories |
Derives d'indazole inhibant trpv1, et leur utilisation
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
CA2664335C
(fr)
|
2006-09-20 |
2014-12-02 |
Boehringer Ingelheim International Gmbh |
Inhibiteurs de la rho-kinase
|
EP2073803B1
(fr)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
WO2008044045A1
(fr)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
US8071779B2
(en)
|
2006-12-18 |
2011-12-06 |
Inspire Pharmaceuticals, Inc. |
Cytoskeletal active rho kinase inhibitor compounds, composition and use
|
US20100022517A1
(en)
*
|
2006-12-18 |
2010-01-28 |
Richards Lori A |
Ophthalmic formulation of rho kinase inhibitor compound
|
JP2010513557A
(ja)
*
|
2006-12-20 |
2010-04-30 |
アボット・ラボラトリーズ |
疼痛治療のためのtrpv1バニロイド受容体アンタゴニストとしてのn−(5,6,7,8−テトラヒドロナフタレン−1−イル)尿素誘導体および関連化合物
|
US8455513B2
(en)
|
2007-01-10 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-aminoisoquinoline compounds
|
WO2008106594A2
(fr)
*
|
2007-02-28 |
2008-09-04 |
The Arizona Board Of Regents, On Behalf Of The University Of Arizona |
Inhibiteurs de la nucléophosmine (npm) et procédés d'induction de l'apoptose
|
CN101622015A
(zh)
|
2007-03-05 |
2010-01-06 |
协和发酵麒麟株式会社 |
药物组合物
|
US8648069B2
(en)
|
2007-06-08 |
2014-02-11 |
Abbvie Inc. |
5-substituted indazoles as kinase inhibitors
|
CN101790526A
(zh)
*
|
2007-06-08 |
2010-07-28 |
雅培制药有限公司 |
用作激酶抑制剂的5-杂芳基取代的吲唑化合物
|
EP2214675B1
(fr)
|
2007-10-25 |
2013-11-20 |
Genentech, Inc. |
Procédé de préparation de composés de thiénopyrimidine
|
US8455514B2
(en)
|
2008-01-17 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-and 7-amino isoquinoline compounds and methods for making and using the same
|
EP2323989A4
(fr)
*
|
2008-03-20 |
2011-06-22 |
Abbott Lab |
Procédés de préparation d'agents destinés au système nerveux central qui sont des antagonistes des trpv1
|
KR101269393B1
(ko)
|
2008-04-28 |
2013-05-29 |
아사히 가세이 파마 가부시키가이샤 |
페닐프로피온산 유도체 및 이의 용도
|
US8106039B2
(en)
*
|
2008-04-30 |
2012-01-31 |
The Trustees Of The University Of Pennsylvania |
Metal complex phosphatidyl-inositol-3-kinase inhibitors
|
US8450344B2
(en)
|
2008-07-25 |
2013-05-28 |
Aerie Pharmaceuticals, Inc. |
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
|
ES2465971T3
(es)
|
2009-04-06 |
2014-06-09 |
University Health Network |
Inhibidores de quinasa y método para tratar cáncer con los mismos
|
ES2553827T3
(es)
|
2009-05-01 |
2015-12-14 |
Aerie Pharmaceuticals, Inc. |
Inhibidores de mecanismo doble para el tratamiento de enfermedad
|
JP2013501792A
(ja)
*
|
2009-08-10 |
2013-01-17 |
サミュメッド リミテッド ライアビリティ カンパニー |
Wnt/b−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
|
DK2987487T3
(da)
*
|
2009-08-10 |
2020-12-07 |
Samumed Llc |
Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
|
UY33001A
(es)
|
2009-11-06 |
2011-05-31 |
Boehringer Ingelheim Int |
Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
|
CA2986631C
(fr)
|
2009-12-21 |
2020-06-02 |
Samumed, Llc |
1h-pyrazolo[3,4-b]pyridines et leurs utilisations therapeutiques
|
TWI516262B
(zh)
|
2010-04-06 |
2016-01-11 |
健康網路大學 |
激酶抑制劑及以其治療癌症的方法
|
WO2012020725A1
(fr)
*
|
2010-08-10 |
2012-02-16 |
塩野義製薬株式会社 |
Dérivé hétérocyclique présentant un antagonisme pour le récepteur npy y5
|
ES2879314T3
(es)
|
2010-08-18 |
2021-11-22 |
Biosplice Therapeutics Inc |
Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina
|
TWI537258B
(zh)
|
2010-11-05 |
2016-06-11 |
百靈佳殷格翰國際股份有限公司 |
六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物
|
CA2819373A1
(fr)
|
2010-12-09 |
2012-06-14 |
Amgen Inc. |
Composes bicycliques en tant qu'inhibiteurs de pim
|
WO2012129338A1
(fr)
|
2011-03-22 |
2012-09-27 |
Amgen Inc. |
Composés d'azole utilisés en tant qu'inhibiteurs des pim
|
JP2014509660A
(ja)
*
|
2011-04-01 |
2014-04-21 |
ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション |
PDK1キナーゼの阻害剤としての置換3−(1H−ベンゾ{d}イミダゾール−2−イル)−1H−インダゾール類似体
|
BR112014006127A2
(pt)
|
2011-09-14 |
2017-04-04 |
Samumed Llc |
indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização wnt/b-catenina
|
WO2013063321A1
(fr)
|
2011-10-25 |
2013-05-02 |
The General Hospital Corporation |
Inhibiteurs de la voie wnt/b-caténine et leurs procédés d'utilisation
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
CN104271133B
(zh)
|
2012-05-04 |
2017-10-13 |
萨穆梅德有限公司 |
1H‑吡唑并[3,4‑b]吡啶及其治疗应用
|
WO2014041518A1
(fr)
*
|
2012-09-14 |
2014-03-20 |
Glenmark Pharmaceuticals S.A. |
Composés thiénopyrrole comme inhibiteurs de l'itk
|
EP2943198B1
(fr)
|
2013-01-08 |
2019-07-17 |
Samumed, LLC |
Inhibiteurs de 3-(benzoimidazol-2-yl)-indazole de la voie de signalisation par wnt et leurs utilisations thérapeutiques
|
CN104370889A
(zh)
*
|
2013-01-24 |
2015-02-25 |
韩冰 |
一类降低眼压的化合物及其制备方法和用途
|
JP6401189B2
(ja)
|
2013-02-22 |
2018-10-03 |
サミュメッド リミテッド ライアビリティ カンパニー |
Wnt/β−カテニンシグナル伝達経路活性化剤としてのγ−ジケトン
|
WO2014134774A1
(fr)
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
|
WO2014134776A1
(fr)
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
|
US9440952B2
(en)
|
2013-03-04 |
2016-09-13 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
WO2014134772A1
(fr)
*
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
|
CN109528721B
(zh)
|
2013-03-15 |
2021-10-01 |
爱瑞制药公司 |
联合治疗
|
EP3027605B1
(fr)
|
2013-07-31 |
2017-11-08 |
Council of Scientific & Industrial Research |
Nouveaux composés d'indazole et leur procede de preparation
|
KR102195494B1
(ko)
|
2013-10-18 |
2020-12-28 |
유니버시티 헬스 네트워크 |
췌장암 치료
|
CN106687454B8
(zh)
|
2014-07-24 |
2019-08-30 |
贝达医药公司 |
作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
|
EP3206686B1
(fr)
|
2014-08-20 |
2019-10-09 |
Samumed, LLC |
Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau
|
WO2016040180A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040182A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
|
WO2016040188A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040181A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040184A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040193A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
|
WO2016040185A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
|
WO2016040190A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
|
GB201506658D0
(en)
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
GB201506660D0
(en)
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
GB201511382D0
(en)
|
2015-06-29 |
2015-08-12 |
Imp Innovations Ltd |
Novel compounds and their use in therapy
|
WO2017024004A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
WO2017024015A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
US10206908B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023993A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10195185B2
(en)
|
2015-08-03 |
2019-02-05 |
Samumed, Llc |
3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023986A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017023989A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023988A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
CN107922349B
(zh)
*
|
2015-08-07 |
2021-05-07 |
哈尔滨珍宝制药有限公司 |
作为fgfr和vegfr抑制剂的乙烯基化合物
|
WO2017079759A1
(fr)
|
2015-11-06 |
2017-05-11 |
Samumed, Llc |
2-(3h-indazol-3-yl)-1h-imidazo[4,5-c]pyridines et leurs utilisations anti-inflammatoires
|
US9643927B1
(en)
|
2015-11-17 |
2017-05-09 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
JP6832946B2
(ja)
|
2015-11-17 |
2021-02-24 |
アエリエ ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤およびその中間体の調製方法
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
AR108326A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
CN109476660B
(zh)
|
2016-06-01 |
2023-04-04 |
拜斯丽治疗有限公司 |
N-(5-(3-(7-(3-氟苯基)-3h-咪唑并[4,5-c]吡啶-2-基)-1h-吲唑-5-基)吡啶-3-基)-3-甲基丁酰胺的制备方法
|
US11078192B2
(en)
|
2016-07-05 |
2021-08-03 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd. |
Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
|
WO2018013430A2
(fr)
|
2016-07-12 |
2018-01-18 |
Arisan Therapeutics Inc. |
Composés hétérocycliques pour le traitement d'une infection à arenavirus
|
EP3506890A1
(fr)
|
2016-08-31 |
2019-07-10 |
Aerie Pharmaceuticals, Inc. |
Compositions ophtalmiques
|
CA3041291A1
(fr)
*
|
2016-10-21 |
2018-04-26 |
Samumed, Llc |
Procedes d'utilisation d'indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation wnt/s-catenine
|
US10758523B2
(en)
|
2016-11-07 |
2020-09-01 |
Samumed, Llc |
Single-dose, ready-to-use injectable formulations
|
SG11201908179UA
(en)
|
2017-03-31 |
2019-10-30 |
Aerie Pharmaceuticals Inc |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
US10604514B2
(en)
|
2017-10-19 |
2020-03-31 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
WO2019084497A1
(fr)
|
2017-10-27 |
2019-05-02 |
Samumed, Llc |
6-(hétéroaryle et aryle à 6 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
|
US10413537B2
(en)
|
2017-10-27 |
2019-09-17 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
|
US10703748B2
(en)
|
2017-10-31 |
2020-07-07 |
Samumed, Llc |
Diazanaphthalen-3-yl carboxamides and preparation and use thereof
|
JP7293560B2
(ja)
|
2017-12-29 |
2023-06-20 |
グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド |
芳香族ビニルまたは芳香族エチル系誘導体、その製造方法、中間体、薬物組成物および使用
|
BR112020017087A2
(pt)
|
2018-02-23 |
2020-12-22 |
Samumed, Llc |
Indazol-3-carboxamidas substituídas 5-heteroarila e preparação e uso das mesmas
|
US10759799B2
(en)
|
2018-06-15 |
2020-09-01 |
Samumed, Llc |
Indazole containing macrocycles and therapeutic uses thereof
|
WO2020056345A1
(fr)
|
2018-09-14 |
2020-03-19 |
Aerie Pharmaceuticals, Inc. |
Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
|
WO2020150545A1
(fr)
|
2019-01-17 |
2020-07-23 |
Samumed, Llc |
DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
|
WO2021088859A1
(fr)
*
|
2019-11-06 |
2021-05-14 |
暨南大学 |
Composé d'indazole, composition pharmaceutique de celui-ci et ses applications
|
WO2021125229A1
(fr)
*
|
2019-12-17 |
2021-06-24 |
富士フイルム株式会社 |
Composé d'indazole ou sel de celui-ci, et composition pharmaceutique
|
WO2021121420A1
(fr)
*
|
2019-12-20 |
2021-06-24 |
江苏凯迪恩医药科技有限公司 |
Composé benzopyrazole et intermédiaire, procédé de préparation correspondant et utilisation associée
|
WO2021168341A1
(fr)
|
2020-02-21 |
2021-08-26 |
Samumed, Llc |
Formes solides de 1-(5-(3-(7-(3-fluorophényl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-diméthylméthanamine
|
CN112724134B
(zh)
*
|
2021-01-14 |
2022-04-01 |
复旦大学 |
氮杂吲唑联吡啶衍生物髓细胞增殖抑制剂及其制备方法与在制药中的应用
|
WO2023240138A1
(fr)
*
|
2022-06-08 |
2023-12-14 |
Blossomhill Therapeutics, Inc. |
Macrocycles contenant de l'indazole et leur utilisation
|